Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 18Pancreatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Glioblastoma 6Gliosarcoma 5Brain Neoplasms 5Astrocytoma 5Oligodendroglioma 4Adenocarcinoma of Lung 4Rectal Neoplasms 3Neoplasms 3Head and Neck Neoplasms 3Glioma 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Salivary Gland Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Spinal Cord Neoplasms 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Precancerous Conditions 1Pharyngeal Neoplasms 1Paranasal Sinus Neoplasms 1

Interventions

seribantumab 1pembrolizumab 1enzalutamide 1Paroxetine 1Itraconazole 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lethal Congenital Contracture Syndrome 2 × Erlotinib Hydrochloride × Clear all
NCT00994123 2016-08-22

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Merrimack Pharmaceuticals

Phase 1/2 Completed
162 enrolled 11 charts
Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡